Elena Sendino Garví was born in Palma de Mallorca, Spain. She followed a bachelor’s degree in Biology in Madrid (Universidad Autónoma de Madrid, UAM), where she specialized in cancer biology and genetics. Afterwards, she followed a research master’s in Health Sciences and a master’s in Biomedical Sciences at Maastricht University (the Netherlands), where she focused on clinical trial design, data mining, high-throughput drug screening and rare genetic diseases. Currently, she is a PhD candidate at the Utrecht Institute for Pharmaceutical Sciences (UIPS), in Utrecht, the Netherlands. Her project focuses on kidney ciliopathies and tubulopathies, with the aim of using drug repurposing approaches and gene-editing (Crispr-Cas9) to restore the cell function of these kidney conditions. At the moment, she is currently working on the development a new 3-D bioengineered model for nephropathic cystinosis, in addition to the restoration the gene function and phenotype of cystinotic cell lines using Crispr-Cas9 HITI approach.